HomeIndustriesHealthcareMadrigal Pharma (MDGL) CFO on Runaway Growth in Liver Disease Treatment

Madrigal Pharma (MDGL) CFO on Runaway Growth in Liver Disease Treatment

Mardi Dier, CFO of Madrigal Pharmaceuticals (MDGL), spotlights their latest quarter and the launch of their first product. Their drug treats liver disease (specifically MASH), and she says they are already on track for $1 billion in sales. Mardi also highlights their strong balance sheet, international expansion, and an extended patent. She stresses that there are millions of patients living with MASH, and there are few other therapies in the field.

Market On Close

04 Dec 2025

SHARE

ON AIR
8:30 am
Market On Close
replay
12:00 am
Market Overtime
REPLAY
12:30 am
Market On Close
REPLAY
2:00 am
Market Overtime
REPLAY
2:30 am
Market Overtime
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
5:00 am
Market Overtime
REPLAY
5:30 am
The Wrap
REPLAY
education
7:00 am
Schwab 2026 Outlook
REPLAY
8:00 am
Market Overtime
REPLAY
ON AIR
8:30 am
Market On Close
REPLAY
education
10:00 am
Schwab 2026 Outlook
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
1:00 pm
Market Overtime
REPLAY
1:30 pm
The Wrap
REPLAY
education
3:00 pm
Schwab 2026 Outlook
REPLAY
4:00 pm
Market Overtime
REPLAY
4:30 pm
Market On Close
REPLAY
education
6:00 pm
Schwab 2026 Outlook
REPLAY
7:00 pm
Fast Market
REPLAY
8:00 pm
Next Gen Investing
REPLAY
9:00 pm
Market Overtime
REPLAY
9:30 pm
The Wrap
REPLAY
education
11:00 pm
Schwab 2026 Outlook
REPLAY

Schwab Network's Newsletters

Daily insights for every investor